Form 8-K - Current report:
SEC Accession No. 0001628280-24-043500
Filing Date
2024-10-24
Accepted
2024-10-24 08:04:24
Documents
14
Period of Report
2024-10-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prme-20241024.htm   iXBRL 8-K 27655
2 EX-99.1 a10-24x2024xesgctpressrele.htm EX-99.1 23861
  Complete submission text file 0001628280-24-043500.txt   186516

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20241024.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20241024_lab.xml EX-101.LAB 22531
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20241024_pre.xml EX-101.PRE 13055
16 EXTRACTED XBRL INSTANCE DOCUMENT prme-20241024_htm.xml XML 2913
Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 241390783
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)